Hengrui Kailera Ribupatide ADA 2026 Data

Key Takeaways

• Oral Phase 2 (n=166) met its primary endpoint: week-26 efficacy-estimand weight loss of 6.9%/12.1%/12.1% at 10/25/50 mg versus 2.3% placebo.
• Up to 38.6% of participants on 25 mg oral achieved ≥15% weight loss (treatment-policy estimand); vomiting rates were 11.4% (25 mg) and 7.5% (50 mg).
• Kailera’s Australia Phase 1 SAD injection study (n=49) showed similar exposure and weight reduction in Asian and non-Asian participants after a single dose.
• Injectable ribupatide is in global KaiNETIC Phase 3; Hengrui plans China oral Phase 3 in 2026, with Kailera targeting global oral Phase 3 as early as 1H 2027.

What did Hengrui report for oral ribupatide at ADA 2026?

Per the partners’ June 5, 2026 GlobeNewswire release, Hengrui’s once-daily oral ribupatide Phase 2 trial in China enrolled 166 adults with obesity (BMI ≥28 kg/m²) without type 2 diabetes. Mean baseline weight was 92.6 kg and BMI 33.3 kg/m²; 63% of participants were female.

Participants were randomized equally to 10 mg, 25 mg, 50 mg, or placebo, with titration to 10/25 mg by week 4 and 50 mg by week 8. The trial identifier listed in the release is NCT06841445.

• Efficacy estimand week-26 mean weight loss: 6.9% / 12.1% / 12.1% vs 2.3% placebo
• Treatment-policy estimand: 6.7% / 11.9% / 11.4% vs 2.1% placebo
• ≥10% responders (treatment policy): 31.0% / 59.1% / 52.5%
• ≥15% responders: 4.8% / 38.6% / 37.5%

No permanent discontinuations or down-titrations due to GI adverse events were reported on oral ribupatide in that disclosure.

How did Kailera’s injectable Phase 1 bridging study read out?

Kailera’s Phase 1 single-ascending-dose study (NCT07044401) enrolled 49 participants in Australia (55% female; mean weight 80 kg; mean BMI 27.6 kg/m²). Non-Asian cohorts received single 1, 2, or 3 mg subcutaneous doses or placebo; Asian participants received 2 mg or placebo, without titration, and were followed to day 29.

Key disclosed findings:

• Safety/tolerability described as similar in Asian and non-Asian participants
• No serious TEAEs, discontinuations, deaths, or severe TEAEs reported
• Weight-adjusted AUC and Cmax similar across ancestry groups
• Day-29 mean weight loss 1.4% (1 mg) to 5.5% (3 mg) vs 0.4% placebo

The companies position this as the first ribupatide injection clinical data generated outside China and as support for the ongoing KaiNETIC Phase 3 program.

What is the correct pharmacology framing for BD teams?

Ribupatide is a dual GLP-1/GIP receptor agonist, not a mono GLP-1 agent. That matters when benchmarking against oral semaglutide or orforglipron. The franchise spans a once-weekly injection (Greater China: HRS9531; ex-China: KAI-9531) and a once-daily oral pill (HRS9531 pill / KAI-9531-T).

Hengrui has submitted an NDA to China’s NMPA for long-term weight management with injectable HRS9531. Kailera holds exclusive rights outside Greater China under a May 2024 agreement cited in the ADA release. Injectable exposure exceeds 2,500 clinical participants with treatment out to 52 weeks in Hengrui-led studies, according to the same wire.

Where do Phase 3 timelines stand after ADA?

Kailera’s KaiNETIC global Phase 3 program for weekly injection is already recruiting, including obesity without diabetes (NCT07284875, ~1,800 planned) and obesity/overweight with diabetes (NCT07284901, ~1,700 planned), both with week-76 primary weight endpoints on ClinicalTrials.gov.

Hengrui said it is advancing oral ribupatide into Phase 3 in China in 2026. Kailera said it plans to start global oral Phase 3 as early as the first half of 2027, subject to FDA and other agency discussions.

What remains unproven?

Oral Phase 2 is China-only at 26 weeks; it does not prove global registrational efficacy or head-to-head superiority versus approved orals. The Australia SAD injection study is single-dose bridging, not a Phase 3 efficacy readout. Competitive “category-leading” language in company materials is aspirational until KaiNETIC and China oral Phase 3 read out with peer-reviewed or regulator-reviewed datasets.

Related NovaPharma coverage

• Novo Nordisk launches Wegovy in China: obesity market context
• Analysis of BMS-Hengrui’s $15B deal
• Pfizer berobenatide Phase 2b monthly dosing

Frequently Asked Questions

Primary Sources

1. GlobeNewswire: Hengrui and Kailera ribupatide ADA 2026 data
2. ClinicalTrials.gov: NCT06841445 oral ribupatide Phase 2
3. ClinicalTrials.gov: NCT07044401 ribupatide injection Phase 1 SAD
4. ClinicalTrials.gov: NCT07284875 KaiNETIC Phase 3 obesity